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Patients with Alzheimer’s disease vary in their ability to sustain cognitive abilities in the presence of brain pathology. A major open
question is which brain mechanisms may support higher reserve capacity, i.e. relatively high cognitive performance at a given level
of Alzheimer’s pathology. Higher functional MRI-assessed functional connectivity of a hub in the left frontal cortex is a core
candidate brain mechanism underlying reserve as it is associated with education (i.e. a protective factor often associated with
higher reserve) and attenuated cognitive impairment in prodromal Alzheimer’s disease. However, no study has yet assessed whether
such hub connectivity of the left frontal cortex supports reserve throughout the evolution of pathological brain changes in
Alzheimer’s disease, including the presymptomatic stage when cognitive decline is subtle. To address this research gap, we obtained
cross-sectional resting state functional MRI in 74 participants with autosomal dominant Alzheimer’s disease, 55 controls from the
Dominantly Inherited Alzheimer’s Network and 75 amyloid-positive elderly participants, as well as 41 amyloid-negative cognitively
normal elderly subjects from the German Center of Neurodegenerative Diseases multicentre study on biomarkers in sporadic
Alzheimer’s disease. For each participant, global left frontal cortex connectivity was computed as the average resting state func-
tional connectivity between the left frontal cortex (seed) and each voxel in the grey matter. As a marker of disease stage, we applied
estimated years from symptom onset in autosomal dominantly inherited Alzheimer’s disease and cerebrospinal ﬂuid tau levels in
sporadic Alzheimer’s disease cases. In both autosomal dominant and sporadic Alzheimer’s disease patients, higher levels of left
frontal cortex connectivity were correlated with greater education. For autosomal dominant Alzheimer’s disease, a signiﬁcant left
frontal cortex connectivity  estimated years of onset interaction was found, indicating slower decline of memory and global
cognition at higher levels of connectivity. Similarly, in sporadic amyloid-positive elderly subjects, the effect of tau on cognition was
attenuated at higher levels of left frontal cortex connectivity. Polynomial regression analysis showed that the trajectory of cognitive
decline was shifted towards a later stage of Alzheimer’s disease in patients with higher levels of left frontal cortex connectivity.
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Together, our ﬁndings suggest that higher resilience against the development of cognitive impairment throughout the early stages of
Alzheimer’s disease is at least partially attributable to higher left frontal cortex-hub connectivity.
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Introduction
Biomarker studies in Alzheimer’s disease have revealed a tem-
poral sequence of the development of brain pathologies and
cognitive decline. In autosomal dominantly inherited
Alzheimer’s disease, a successive emergence of abnormal
CSF concentrations of amyloid-b, tau, microglial activation,
grey matter atrophy and cerebral glucose hypometabolism
has been reported (Bateman et al., 2012; Benzinger et al.,
2013; Suarez-Calvet et al., 2016). Similar ﬁndings have
been obtained in sporadic late onset Alzheimer’s disease
(Jack et al., 2012), providing strong evidence for cascading
pathologies that lead to cognitive deﬁcits and ultimately de-
mentia. The extent of cognitive decrease at any level of
Alzheimer’s disease pathologies, however, varies considerably
between individuals (Vemuri et al., 2011; Mufson et al.,
2016). Even in autosomal dominantly inherited Alzheimer’s
disease (ADAD), where the course of Alzheimer’s disease de-
velopment is strongly determined by mutations in genes
encoding presinilin-1 (PSEN1), presenilin-2 (PSEN2) or
amyloid precursor protein (APP), the cognitive status remains
relatively stable in some patients despite advanced levels of
amyloid-b and tau pathology (Lim et al., 2016). The theory
of reserve posits that such a discrepancy between brain path-
ology and cognitive impairment is not a prediction error due
to incomplete detection of neuronal pathologies, but is due to
higher resilience against the effects of pathology (Park and
Reuter-Lorenz, 2009; Stern, 2012). In other words, some
people may show higher ability to maintain cognitive abilities
relatively well at any given level of brain pathology. At the
epidemiological level, more years of education, higher general
cognitive ability, occupational attainment and other cogni-
tively challenging life experiences (Valenzuela and Sachdev,
2006), or higher physical ﬁtness (Okonkwo et al., 2014;
Tolppanen et al., 2015; Duzel et al., 2016) have been asso-
ciated with higher cognitive abilities in ageing and
Alzheimer’s disease. Neuroimaging studies on structural
brain differences showed a larger premorbid brain volume
to be an additional protective factor in Alzheimer’s disease
(Perneczky et al., 2010; Meng and D’Arcy, 2012; Sumowski
et al., 2014). However, protective lifestyle factors and brain
volume are gross measures that are not informative about
protective functional brain mechanisms. Hence, the overall
aim of the current study was to test particular functional
brain features that support higher resilience of cognitive per-
formance during the course of Alzheimer’s disease.
The fronto-parietal control network has been proposed
to play a key role in mental health and reserve in ageing
(Cole et al., 2014; Medaglia et al., 2017). The fronto-
parietal control network harbours major brain hubs (Cole
et al., 2010) and controls the activity of other functional
networks across different cognitive domains (Cole et al.,
2013). Thus, this network may be fundamental for main-
taining efﬁcient functional brain processes that underlie
cognitive performance when brain damage occurs. We re-
cently showed that higher global connectivity of a hub in
the fronto-parietal control network is associated with
higher reserve in amyloid-positive mild cognitively impaired
patients who are at increased risk of developing
Alzheimer’s disease dementia (Franzmeier et al., 2017a).
Speciﬁcally, we showed that higher global functional con-
nectivity of the left frontal cortex (gLFC-connectivity,
Brodmann area 6/44) was associated with: (i) more years
of education (i.e. an epidemiological factor that is asso-
ciated with lower risk of Alzheimer’s disease); and (ii) an
attenuated impact of Alzheimer’s disease-related posterior
parietal glucose hypometabolism on memory performance
(Franzmeier et al., 2017b). Particularly the global func-
tional connectivity of that hub region of the fronto-parietal
control network in the left rather than the right hemisphere
has been related to reserve-associated protective factors
including higher general cognitive ability (i.e. ﬂuid intelli-
gence) and better cognitive control in young to middle-aged
subjects (Cole et al., 2012, 2015). Together, these results
suggest that gLFC-connectivity may contribute to reserve at
an early stage in Alzheimer’s disease, and motivated us to
ask whether gLFC-connectivity is associated with higher
reserve during the entire course of the disease from preclin-
ical Alzheimer’s disease to dementia.
Here, we hypothesized that at higher levels of gLFC-con-
nectivity the level of impairment in global cognition (Mini-
Mental-State Examination, MMSE) and episodic memory
(delayed free recall) are shifted relative to levels of bio-
markers of Alzheimer’s disease related neurodegeneration.
To assess the speciﬁcity of our hypothesis we conducted
control analyses for global connectivity of additional re-
gions including: (i) the LFCs’ right homotopic region (i.e.
right frontal cortex, RFC); and (ii) two null-regions within
the visual and motor cortices for which we did not expect
any signiﬁcant effects. We tested our hypothesis based on
resting state functional MRI data, cognitive and biomarker
levels obtained in two cohorts including: (i) participants
with ADAD recruited within the Dominantly Inherited
Alzheimer Network (DIAN); and (ii) elderly subjects with
sporadic Alzheimer’s disease recruited within the German
Center for Neurodegenerative Diseases longitudinal study
on cognition and dementia (DELCODE). The study
design of DIAN allowed us to examine the association
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between gLFC-connectivity and cognitive performance
against the dynamic changes of biomarkers of Alzheimer’s
disease pathology years before onset of dementia. The in-
clusion of sporadic Alzheimer’s disease provided the oppor-
tunity to test whether any effects of gLFC-connectivity on
reserve can be generalized towards the more common age-
related form of accumulating Alzheimer’s disease pathology
in elderly subjects. Thus, the current cross-sectional study
assessed for the ﬁrst time a core candidate functional brain
substrate underlying higher cognition during the course of
Alzheimer’s disease from preclinical to dementia stages of
Alzheimer’s disease.
Materials and methods
Participants
The DIAN sample of ADAD and controls
Seventy-four mutation carriers exhibiting Alzheimer’s disease
causing mutations in genes PSEN1, PSEN2 or APP, and 55
non-mutation carrier siblings were included from the DIAN
database (Clinical Trial Identiﬁer NCT00869817) (Moulder
et al., 2013). Beyond the inclusion criteria of DIAN, the re-
quirement for inclusion in the current study was the presence
of baseline resting state functional MRI, T1 structural MRI,
CSF biomarker assessments, partial volume corrected global
Pittsburgh compound B-PET (PiB-PET) binding data, and
neuropsychological test scores. Because these stricter inclusion
criteria resulted in the selection of a subsample from the larger
DIAN cohort (n = 177 mutation carriers, and n = 136 non-mu-
tation carriers), we tested for selection bias by comparing base-
line characteristics [age, gender, years of education, estimated
years from symptom onset (EYO)] between the selected sample
(n = 129) and the excluded (n = 184) sample recruited in
DIAN, using two-sample t-tests for continuous and chi-
squared tests for categorical variables. No signiﬁcant (i.e.
P40.05) differences between groups in any of the variables
were found, suggesting that the selected sample is representa-
tive of the DIAN cohort. For details on the entire DIAN
sample versus the selected DIAN sample please see
Supplementary Table 1. Distributions of the main biomarkers
and cognitive test scores of the selected DIAN sample can be
found in Supplementary Fig. 1. The EYO was deﬁned as the
difference between a participant’s age and the parental age of
symptom onset, as an estimate of the number of years until
symptom onset in mutation carriers. The measurement of
global PiB-PET and CSF biomarkers of amyloid-b, tau phos-
phorylated at serine-181 (p-tau181) and total tau have been
described previously (Bateman et al., 2012; Benzinger et al.,
2013). Local ethical approval and written informed consent
had been obtained from each participant by the respective
DIAN centres.
The DELCODE sample of sporadic Alzheimer’s
disease and controls
A total of 116 elderly participants were included from the
DELCODE study encompassing participants with cognitively
normal status (n = 49), subjective cognitive decline (n = 40),
mild cognitive impairment (MCI, n = 14) and Alzheimer’s
disease dementia (n = 13). DELCODE is an ongoing prospect-
ive longitudinal study on the development of neuroimaging
and bioﬂuid-derived markers for the early detection of late
onset sporadic Alzheimer’s disease. The study is conducted at
eight University hospitals within the German Center for
Neurodegenerative Diseases. Participants were deﬁned as cog-
nitively normal when showing a Clinical Dementia Rating of
zero and neither reporting cognitive complaints nor scoring
lower than 1.5 standard deviations (SD) of age-, sex-, and
education-adjusted norms on all subtests of the German
CERAD-NP Plus battery (Berres et al., 2000), which includes
the Trail Making Test versions A and B (Reitan, 1958) and
letter ﬂuency in addition to the original version of the CERAD
battery (Morris et al., 1989). Subjective cognitive decline was
deﬁned by criteria including: (i) Clinical Dementia
Rating40.5; (ii) normal performance on the tests of
CERAD-NP Plus (i.e. a criterion of cognitively normal); and
(iii) subjective experience of cognitive decline between the last
6 months and 5 years as reported in semi-structured interviews
conducted by a physician with the study participant. Mild
cognitive impairment was diagnosed at a Clinical Dementia
Rating40.5 and cognitive performance level being 1.5 SD
below the age- and education adjusted norm for the word-
list delayed recall trial of the CERAD-NP-Plus battery
(Petersen et al., 2014), thus single- and multi-domain amnestic
mild cognitive impairment was included. Alzheimer’s disease
dementia was diagnosed when fulﬁlling the clinical NINDCS/
ADRDA criteria of probable Alzheimer’s disease (McKhann
et al., 2011). All participants included in the current study
underwent lumbar puncture to determine CSF levels of amyl-
oid-b42, amyloid-b40, p-tau181, total tau and were a priori
dichotomized as showing either normal or abnormal CSF
amyloid-b levels (CSF amyloid-b + versus CSF amyloid-b),
based on the previously established cut-off for CSF amyloid-
b42/40 ratio50.1 (Janelidze et al., 2016). All participants had
to have complete baseline data available including resting state
functional MRI, T1 structural MRI, CSF biomarker levels, and
neurocognitive test scores. When testing for selection bias by
comparing baseline characteristics (age, gender, education) be-
tween the selected sample (n = 116) and the excluded sample
(n = 250) using two-sample t-tests for continuous and chi-
squared tests for categorical variables, no signiﬁcant (i.e.
P4 0.05) differences between groups in any of the variables
were found, suggesting that the selected sample is representa-
tive of the whole DELCODE cohort. Details of the entire
versus the selected DELCODE sample can be found in
Supplementary Table 2. Biomarkers and cognitive test score
distributions of the selected DELCODE sample are illustrated
in Supplementary Fig. 1.
Assessment of general cognitive
ability and memory performance
As a measure of general cognitive function, we used the
MMSE score (Folstein et al., 1975). For episodic memory,
the delayed free recall test included in the Wechsler Memory
Scale Logical Memory II test was used (Kent, 2013). These
two measures of global cognition and episodic memory were
selected from a larger set of psychometric tests since those tests
were obtained in both DIAN and DELCODE and thus yielded
comparability between both studies.
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MRI acquisition
In both DIAN and DELCODE, all MRI scans were acquired on
3T MRI systems (Siemens) with uniﬁed scanning protocols for
each study. High resolution structural images were obtained
using a T1-MPRAGE sequence (DIAN: repetition time/echo
time = 2300ms/2.95ms, ﬂip angle = 9, 1.1  1.1  1.2mm
voxels; DELCODE: repetition time/echo time = 2500ms/
4.33ms, ﬂip angle = 7, 1mm isotropic voxels) with whole-
brain coverage. Resting state functional MRI images were re-
corded using a T2*-weighted EPI sequence (DIAN: repetition
time/echo time = 2230ms/30ms, ﬂip angle = 80, 3.3mm iso-
tropic voxels, 140 volumes; DELCODE: repetition time/echo
time = 2580ms/30ms, ﬂip angle = 80, 3.5mm isotropic
voxels, 180 volumes). In DELCODE, the participants were in-
structed to keep their eyes closed and not to fall asleep prior to
the resting state scan. In DIAN, resting state functional MRI
was acquired with eyes open.
MRI preprocessing and connectivity
analysis
The same processing pipelines were applied to the MRI scans
from the DIAN and DELCODE cohort. Note that all process-
ing steps were conducted separately for each sample, i.e. no
data were pooled across DELCODE and DIAN but analysed
separately within each study.
Preprocessing of structural MRI and spatial
normalization
T1 MRI images were spatially normalized using SPM12
(Wellcome Trust Centre for Neuroimaging, University
College London, UK: www.ﬁl.ion.ucl.ac.uk/spm). In a ﬁrst
step, T1-weighted images were segmented into probabilistic
tissue maps of grey matter, white matter and CSF compart-
ments (Ashburner and Friston, 2005). Non-linear spatial nor-
malization parameters were estimated using SPM’s DARTEL
toolbox (Ashburner, 2007), yielding a sample-speciﬁc template
that was subsequently registered to a template in MNI stand-
ard space in order to estimate afﬁne transformation param-
eters. In a next step, the non-linear DARTEL and afﬁne
transformation parameters were jointly applied to the seg-
mented grey matter maps to obtain participant speciﬁc grey
matter maps in MNI space. All grey matter maps in MNI
space were then averaged and binarized at a voxel value
40.3 to obtain a sample-speciﬁc grey matter mask for func-
tional connectivity analyses.
As a surrogate for regional brain atrophy that is highly
related to Alzheimer’s disease pathology and to memory im-
pairment (Petersen et al., 2000), we assessed the volumes of
the bilateral hippocampi using T1 MRI data, applying a pre-
viously described fully automated approach that was validated
using manual segmentation (Mak et al., 2011). For details, see
Supplementary material.
Preprocessing of resting state functional MRI data
All functional images were visually inspected for artefacts prior
to analyses. For each participant, all functional MRI volumes
were slice-time corrected, realigned to the ﬁrst volume, and
subsequently registered to the native space high resolution
3D T1-weighted image. The non-linear (i.e. DARTEL) and
afﬁne registration transformation matrix were again jointly
applied to the registered functional MRI volumes to spatially
normalize all images to MNI space followed by a smoothing
step with an 8mm full-width at half-maximum Gaussian
kernel. To remove noise from the spatially normalized resting
state functional MRI data, we removed the linear trend
and applied a band-pass ﬁlter with a frequency band of
0.01–0.08Hz. Additionally, we regressed out the six motion
parameters and the functional MRI signal averaged across the
white matter and CSF. Since functional connectivity analyses
can be potentially confounded by motion even after realign-
ment and motion regression (Power et al., 2012), we per-
formed motion scrubbing following a previously established
protocol (Power et al., 2014). To this end, we computed the
framewise displacement (i.e. the average spatial displacement
between two adjacent volumes) for each volume of the resting
state scan. Volumes that exhibited a framewise displacement
40.5mm were censored together with one preceding and two
subsequent volumes. Participants for whom 430% of the rest-
ing-state volumes had to be censored after scrubbing were not
included in the current study.
Assessment of global connectivity
GLFC-connectivity was assessed via seed-based functional con-
nectivity analysis following a previously described approach
(Cole et al., 2012; Franzmeier et al., 2017b). In brief, we
created a binary sphere centred around the left frontal cortex
(LFC) (MNI: x = 42, y = 6, z = 28; Brodmann area 6/44;
Fig. 1) with a radius of 8mm, which was used as the seed
region for connectivity analyses. The LFC seed region of inter-
est was superimposed onto the preprocessed, scrubbed and
grey matter-masked resting state functional MRI data to ex-
tract the mean functional MRI time series within the LFC
region of interest. Next, we calculated Fisher z-transformed
Pearson moment correlations between the LFC-region of inter-
est time series and each remaining grey matter voxel. To
obtain the gLFC-connectivity score, we averaged all positive
correlations across voxels belonging to the grey matter for
each participant consistent with our and others previous ana-
lyses of gLFC-connectivity (Cole et al., 2012; Franzmeier et al.,
2017a, b). Note that negative connections were not included,
since positive and negative connectivity values would cancel
each other out during averaging. In addition to the LFC,
global connectivity was also computed for three control re-
gions of interest: (i) the LFCs’ right hemispheric homotopic
region (i.e. RFC, x = 42, y = 6, z = 28) to test left hemispheric
speciﬁcity; and (ii) two null regions including one in the oc-
cipital pole (x = 19, y = 102, z = 3), as well as M1 in the
motor cortex (x = 38, y = 22, z = 56). Note that we used
group-speciﬁc rather than subject-speciﬁc regions of interest
for the current analyses, since there is to date no reliable
gold-standard on how to deﬁne subject-speciﬁc functional clus-
ters that may serve as individual seed-regions of interest.
To address potentially confounding effects of multi-site func-
tional MRI acquisition we included centre as a random effect
in our main analyses. In addition, we tested for each study
(DIAN and DELCODE) whether global connectivity scores
differed between scanner models (Verio, Trio, Prisma in
DIAN and Verio, Trio, Skyra in DELCODE) using
ANCOVAs controlling for age, gender and education. Here,
no signiﬁcant differences in global connectivity were detected
between scanner models for the LFC [DIAN: F(4,124) = 0.176,
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P = 0.839; DELCODE F(4,111) = 0.674, P = 0.570], the RFC
[DIAN: F(4,124) = 0.144, P = 0.867; DELCODE: F(4,111)
= 0.361, P = 0.549], the occipital pole [DIAN: F(4,124) =
2.254, P = 0.109; DELCODE: F(4,111) = 0.1.419, P = 0.241]
or M1 [DIAN: F(4,124) = 0.219, P = 0.804; DELCODE:
F(4,111) = 1.240, P = 0.299].
Statistical analysis
Demographics and cognitive scores were compared between
mutation carriers and non-mutation carriers within the DIAN
study and between diagnostic groups within the DELCODE
study, using ANOVAs (for comparisons between more than
two groups), two-sample t-tests (for two groups) and chi-
square tests (for categorical variables). GLFC-connectivity,
CSF-tau, CSF-p-tau181 and global partial-volume corrected
PIB-PET uptake measures were log- and z-transformed, after
which there were no deviations from a normal distribution as
assessed via Shapiro-Wilk tests. All subsequent analyses were
performed using these transformed values. Note that no data
were pooled across the DIAN or DELCODE sample for our
analyses.
Next, we tested whether the effect of Alzheimer’s disease
severity on cognitive ability is attenuated at higher levels of
gLFC-connectivity. For DIAN, the primary linear mixed effects
models included the interaction term EYO  gLFC-connectivity
and main effects of these variables on either MMSE or logical
memory delayed free recall. As a secondary measure of dis-
ease stage, we used CSF-tau instead of EYO. All linear
mixed effects models were tested separately in mutation carrier
and non-mutation carrier groups and were adjusted for gender
and family afﬁliation as ﬁxed effects, and centre as a random
effect.
To test whether the gLFC-connectivity  EYO interaction
term improves the model ﬁt, we compared the full model to
the reduced model that did not include the interaction term as
a predictor. We compared the Akaike information criterion
between the full and the reduced model to assess whether
including the interaction term yielded a lower Akaike informa-
tion criterion, indicating a better model ﬁt. Consistent with the
approach in previous DIAN studies (Bateman et al., 2012), age
was not included in the models due to collinearity with EYO.
However, DIAN participants are relatively young (mean
age = 37 years), thus ageing is unlikely to account for any ef-
fects of EYO or CSF-tau on cognition in mutation carriers.
These analyses were conducted in an equivalent fashion for
global connectivity of the RFC, the occipital pole and M1.
Next, we modelled the interaction effect (EYO  gLFC-connect-
ivity) on global cognition (i.e. MMSE). In addition, we estimated
the trajectories of biomarker alterations as done previously based
on cross-sectional data (Bateman et al., 2012), so that the course
of cognitive alterations could be compared to that of biomarkers
of Alzheimer’s disease pathological brain differences. In line with a
previous approach (Suarez-Calvet et al., 2016), we ﬁtted polyno-
mial mixed effects models for each outcome variable (MMSE,
CSF-tau, precuneus FDG-PET, global PiB-PET binding, and
hippocampal volume) as a function of EYO, quadratic (EYO2)
and cubic (EYO3) terms, gender, and family afﬁliation as ﬁxed
effects and site as random effect (Bateman et al., 2012), stratiﬁed
for mutation carriers and non-mutation carriers. A ﬁrst order
interaction of EYO  gLFC connectivity was included, in add-
ition, when global cognition was the dependent variable. For
each outcome variable, the best model was chosen based on the
Akaike information criterion. We then plotted the predicted dif-
ference between mutation carriers and non-mutation carriers at
each EYO, divided by the standard deviation of the respective
variable within the pooled sample. Since we adopted the model-
ling approach from previous studies on biomarker changes in
DIAN, the results for the biomarker trajectories were highly con-
sistent with previous reports (Bateman et al., 2012; Benzinger
et al., 2013; Suarez-Calvet et al., 2016). This plot was restricted
to an EYO range between 20 and +10 because of low numbers
of participants at extreme values of EYO and to prevent identiﬁa-
bility of subjects based on extreme values of EYO (as required by
DIAN publication guidelines).
Similarly, for DELCODE, we computed linear mixed effects
models to test the interaction between CSF-tau (as a marker of
disease severity that closely tracks memory decline) (Brier
et al., 2016) and gLFC-connectivity on either MMSE or logical
memory delayed recall, adjusting for age and gender as ﬁxed
effects and for centre as a random effect. These models were
computed separately in the control (CSF amyloid-b) and
Alzheimer’s disease (CSF amyloid-b + ) groups. In addition,
we computed reduced models without the interaction term as
a predictor and assessed differences in the model ﬁt
(i.e. Akaike information criterion) between the full and the
respective reduced model. Separate models were computed
for each dependent variable including global connectivity of
the RFC, the occipital pole and M1. In an exploratory
Figure 1 Seed-based LFC connectivity pattern. Surface
renderings of significant LFC-connectivity in the DIAN and
DELCODE sample at a voxel threshold of a5 0.001, family-wise
error corrected at the cluster level at a5 0.05. The LFC-region of
interest that was used for seed-based functional connectivity ana-
lyses is superimposed as a blue sphere on the left hemisphere.
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analysis, we additionally tested the effect of global connectiv-
ity  CSF-tau on the word-list delayed recall subscale of
the ADAS-Cog battery, which was only available in the
DELCODE sample.
To model the effect of gLFC-connectivity on the trajectories
of cognitive changes across increasing disease severity (CSF-tau
levels), we applied the same polynomial mixed effects approach
as used in the DIAN sample, this time stratiﬁed by CSF-amyl-
oid-b status. That is, we computed polynomial mixed effects
models including CSF-tau (quadratic and cubic terms), con-
trolled for age, gender (ﬁxed effects) and centre (random
effect) to predict biomarkers (i.e. CSF-amyloid-b42/40 ratio, hip-
pocampal volume). A ﬁrst order interaction of CSF-tau  gLFC
connectivity was included, in addition, when MMSE was the
dependent variable.
A schematic illustration of these above described main ana-
lyses is illustrated in Supplementary Fig. 2.
In additional models, we tested whether education (as a pro-
tective factor associated with higher reserve) predicted gLFC-
connectivity in both samples, DIAN and DELCODE. These
analyses were adjusted for gender and centre (random effect)
as well as EYO and family afﬁliation in DIAN and age in
DELCODE.
All analyses were computed using the freely available R statis-
tical software package (http://www.r-project.org) (R Core Team,
2014), standardized beta coefﬁcients were considered signiﬁcant
when meeting an alpha-threshold of a50.05. For our main ana-
lyses of the interaction gLFC-connectivity times Alzheimer’s dis-
ease severity (i.e. EYO or CSF-tau) on global cognition (i.e.
MMSE) and episodic memory (i.e. logical memory delayed
recall) (four analyses across two samples), we applied a
Bonferroni-corrected alpha-threshold of a50.0125.
Results
Sample characteristics
Baseline characteristics and group differences are displayed
in Table 1 for DIAN and Table 2 for DELCODE. Positive
functional connectivity of the LFC seed region to other
brain regions covered primarily the fronto-parietal control
network in both the DIAN and DELCODE samples
(Fig. 1), consistent with our previous work (Franzmeier
et al., 2017b).
DIAN
To test our major hypothesis that greater gLFC-connectiv-
ity moderates the impact of Alzheimer’s disease pathology
on cognition in the mutation carrier group of the DIAN
sample, we used linear mixed effects models, where we
tested the interaction between gLFC-connectivity and
EYO on cognitive measures. We found a signiﬁcant inter-
action of gLFC-connectivity  EYO on both MMSE
[b/standard error (SE) = 0.269/0.099, P = 0.008; Fig. 2A]
and logical memory delayed free recall (b/SE = 0.275/
0.106, P = 0.012; Fig. 2B). The full-models including the
interaction term showed a better model ﬁt (i.e. Akaike
information criterion) as compared to the reduced models
for MMSE (186.6 versus 192.1) and logical memory
delayed free recall (182.8 versus 186.3). Visual inspection
of Fig. 2A and B reveals that at higher levels of gLFC-
connectivity, higher EYO (i.e. closer proximity to the
estimated age of symptom onset) was associated with rela-
tively less decline in MMSE and logical memory delayed
free recall when compared to those with lower levels of
gLFC-connectivity within the mutation carrier group. No
interaction effect of EYO  gLFC-connectivity on any cog-
nitive measures was found in the non-mutation carrier
group. When using CSF-tau instead of EYO as a marker
of disease stage (data not shown in Fig. 2), we found a
similar result pattern in mutation carriers: at higher levels
of gLFC-connectivity, the impact of CSF-tau on cognition
was attenuated for MMSE (b/SE = 0.314/0.078,
P5 0.001). However, such an effect was not found for
logical memory delayed free recall in the mutation carrier
group. For the non-mutation carrier group, no signiﬁcant
interaction between CSF-tau and gLFC-connectivity on any
cognitive measure was observed. All abovementioned ana-
lyses were conducted equivalently for the control regions
including the RFC, the occipital pole and M1. For the RFC,
we found similar but less strong effects as for the LFC, i.e.
a signiﬁcant interaction gRFC-connectivity  EYO on
Table 1 Baseline characteristics of the DIAN sample of ADAD and controls
ADAD-MC ADAD-NC Cohen’s d T-value P-value
(n = 74) (n = 55)
Age 37.49 (10.05) 37.84 (10.31) 0.034 0.193 0.848
Gender (female/male) 42/32 34/21 0.563
Years of education 14.47 (3.2) 15.51 (2.16) 0.38 2.19 0.030
EYO 9.82 (11.00) 9.61 (11.77) 0.02 0.104 0.919
Global PiB-PET 2.12 (1.25) 1.04 (0.05) 1.22 6.430 50.001
CSF-tau 110 (89.48) 55.19 (22.2) 0.84 4.439 50.001
CSF-p-tau181 60.82 (35.58) 29.77 (9.41) 1.19 6.305 50.001
gLFC-connectivity 0.27 (0.07) 0.30 (0.07) 0.43 2.445 0.016
Logical memory delayed recall 10.08 (6.13) 13.98 (3.71) 0.77 4.168 50.001
MMSE 27.04 (5.1) 29.45 (1.02) 0.66 3.455 50.001
MC = mutation carrier; NC = non-mutation carrier. Values are presented as mean (SD).
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MMSE (b/SE = 0.169/0.078, P = 0.018) but no interaction
on logical memory delayed free recall (b/SE = 0.189/0.112,
P = 0.095). These RFC results, however, did not survive
Bonferroni correction. The full model including the gRFC-
connectivity  EYO interaction term showed a better model
ﬁt (i.e. Akaike information criterion) compared to the
reduced models for MMSE (172.3 versus 179.1). As ex-
pected, no effects were found for the occipital pole or M1.
Table 2 Baseline characteristics of the DELCODE sample of sporadic Alzheimer’s disease
Sporadic AD (Ab+ ) CN SCD Cohen’s d MCI Cohen’s d ADD Cohen’s d F-value P-value
(n = 75) (n = 25) (n = 23) (SCD
versus CN)
(n = 14) (MCI
versus CN)
(n = 13) (ADD
versus CN)
Age 67.76 (5.23)b,c 72.26 (4.16)a 0.95 74.64 (5.34)a 1.30 71.31 (6.18) 0.62 6.160 50.001
Gender (female/male) 16/9 10/13 5/9 9/4 0.164
Years of education 14.64 (2.93) 14.87 (3.81) 0.07 14.71 (3.58) 0.02 14.00 (3.11) 0.21 0.192 0.901
CSF-Ab42/40 ratio 0.08 (0.02)
c,d 0.08 (0.02)c,d 0.00 0.06 (0.02)a,b 1.00 0.04 (0.01)a,b 2.53 15.456 50.001
CSF- tau 357.08 (136.91)c,d 395.16 (178.58)d 0.24 534.97 (172.61)a,d 1.14 818.53 (322.62)a,b,c 1.86 17.616 50.001
CSF-p-tau181 49.08 (17.06)
d 53.96 (25.89)d 0.22 71.99 (21.37)d 1.18 101.6 (45.58)a,b,c 1.53 12.220 50.001
gLFC-connectivity 0.23 (0.05) 0.25 (0.05) 0.40 0.23 (0.05) 0.00 0.22 (0.03) 0.24 1.535 0.213
LM delayed recall 14.57 (8.15)d 12.00 (7.18) 0.33 10.60 (6.47) 0.54 6.69 (7.26)a 1.02 2.905 0.041
MMSE 29.20 (0.96)c,d 29.39 (0.78)c,d 0.22 27.71 (1.68)a,b,d 1.09 23.85 (2.82)a,b,c 2.54 43.066 50.001
Controls (Ab) CN SCD Cohen’s d T-value P-value
(n = 41) (n = 24) (n = 17) (SCD
versus CN)
Age 67.29 (4.6) 71.06 (5.53) 0.74 2.376 0.023
Gender (female/male) 15/9 9/8 0.540
Years of education 14.54 (2.62) 15.35 (3.16) 0.27 0.896 0.392
CSF-Ab42/40 ratio 0.12 (0.02) 0.12 (0.01) 0.00 0.957 0.957
CSF-tau 320.78 (112.02) 355.84 (114.32) 0.31 0.979 0.334
CSF-p-tau181 51.57 (16.28) 50.35 (21.1) 0.06 0.591 0.581
gLFC-connectivity 0.25 (0.06) 0.23 (0.04) 0.39 1.067 0.293
LM delayed recall 16.56 (8.26) 9.06 (2.19) 1.24 1.824 0.076
MMSE 29.67 (0.76) 29.06 (0.9) 0.73 2.336 0.024
Post hoc Tukey test significant (P5 0.05) for aversus cognitively normal (CN); bversus subjective cognitive decline (SCD); cversus mild cognitive impairment (MCI); dversus Alzheimer’s
disease dementia (ADD). Values are presented as mean (SD).
Ab = amyloid-b; LM = logical memory.
Table 3 Summary of linear mixed effects models
b (SE) T-value P-value Overall R2
ADAD-MC
MMSEa
EYO  gLFC-connectivity 0.269 (0.099) 2.721 0.008c 0.498
EYO 0.576 (0.106) 5.359 50.001c
gLFC-connectivity 0.216 (0.094) 2.292 0.025
LM delayed recalla
EYO  gLFC-connectivity 0.275 (0.106) 2.585 0.012c 0.445
EYO 0.458 (0.109) 4.208 50.001c
gLFC-connectivity 0.047 (0.095) 0.494 0.623
Sporadic ADAb+
MMSEb
CSF-tau  gLFC-connectivity 0.285 (0.087) 3.266 0.002c 0.375
CSF-tau 0.553 (0.071) 7.758 50.001c
gLFC-connectivity 0.159 (0.072) 2.207 0.031
LM delayed recallb
CSF-tau  gLFC-connectivity 0.336 (0.126) 2.672 0.011c 0.292
CSF-tau 0.327 (0.111) 2.925 0.005c
gLFC-connectivity 0.011 (0.112) 0.099 0.922
aModel controlled for gender, family ID (fixed effects) and site (random effect).
bModel controlled for age, gender (fixed effects) and site (random effect).
cP5 0.05, Bonferroni corrected.
Ab = amyloid-b; AD = Alzheimer’s disease; LM = Logical memory; MC = mutation carrier; NC = non-mutation carrier.
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Detailed results of these control analyses are summarized
for each control region of interest in Supplementary Tables
3–5.
Figure 3A illustrates the dynamic development of bio-
markers and MMSE in mutation carriers versus non-muta-
tion carriers across EYO, as predicted by polynomial mixed
models based on cross-sectional data (Bateman et al.,
2012). Speciﬁcally, the cross-sectionally estimated temporal
evolution of impairment in global cognition is shown for
mutation carriers with high versus low gLFC-connectivity
as deﬁned by median split. The decline in MMSE in indi-
viduals with high gLFC-connectivity is shifted to a later
time point as compared to individuals with low gLFC-
connectivity.
DELCODE
Next, we aimed to generalize ﬁndings on gLFC-connectivity
to elderly subjects with evidence for sporadic Alzheimer’s
disease pathophysiology (i.e. CSF-amyloid-b + ), hence we
tested whether greater levels of gLFC-connectivity attenuated
the effects of Alzheimer’s disease stage on the same cognitive
measures (i.e. MMSE and logical memory delayed recall) in
the DELCODE sample. Since EYO is not available in spor-
adic Alzheimer’s disease subjects, we used CSF total tau levels
as a marker of disease severity that is closely linked to neu-
rodegeneration and memory decline (Brier et al., 2016). The
interaction gLFC-connectivity  CSF-tau was signiﬁcant
for both global cognition (MMSE: b/SE = 0.285/0.087,
Figure 2 Interaction gLFC-connectivity  Alzheimer’s disease severity on cognition. Scatterplots of the interaction gLFC-
connectivity  Alzheimer’s disease severity on cognitive performance in the ADAD (DIAN) and sporadic Alzheimer’s disease (DELCODE)
sample. For DIAN, the estimated years from symptom onset (EYO) are plotted against the MMSE score (A) and the delayed free recall score of
the logical memory scale (B). For DELCODE, CSF-tau levels are plotted against MMSE (C) and logical memory delayed free recall (D). For
illustrational purposes, groups of high and low gLFC-connectivity (defined via median split) are plotted separately, statistical interactions were
calculated using continuous measures. Dashed lines indicate 95% confidence intervals. P-values of the interaction terms are displayed for each
graph. Ab = amyloid-b.
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P = 0.002; Fig. 2C) and logical memory delayed free recall (b/
SE = 0.336/0.126, P = 0.011; Fig. 2D) within the CSF-amyl-
oid-b + group. The full models including the interaction term
showed a better model ﬁt (i.e. Akaike information criterion)
as compared to the null-model for MMSE (194.0 versus
199.2) and logical memory delayed free recall (212.1 versus
215.4). The scatterplots of the interaction effect (Fig. 2C and
D) show that the effects of CSF-tau on global cognition
(MMSE) and logical memory delayed free recall were attenu-
ated at higher levels of gLFC-connectivity. In an exploratory
analysis in the DELCODE cohort, we detected an interaction
gLFC-connectivity  CSF-tau on ADAS-Cog word-list
delayed recall (b/SE = 0.289/0.137, P = 0.039) that was con-
gruent with our main analyses. When tested in the CSF-amyl-
oid-b control group, all abovementioned interaction models
were non-signiﬁcant. For the RFC, the interaction for gRFC-
connectivity  CSF-tau the results were not signiﬁcant, nei-
ther for logical memory delayed free recall (b/SE = 0.215/
0.121, P = 0.078) nor MMSE (P = 0.47). As expected, no
effects were detected for the occipital pole or M1. Detailed
statistics of these control analyses are displayed for each
region of interest in Supplementary Tables 3–5.
Figure 3B illustrates the change in cognition and bio-
markers across the spectrum of CSF-tau levels as predicted
by polynomial mixed effects models. With increasing CSF-
tau concentrations, there is a decrease in CSF-amyloid-b42/40
ratio and hippocampal volume indicating more progressed
Alzheimer’s disease. Similar to the results in DIAN, the
cross-sectionally estimated trajectory of the decline in
MMSE is shifted to a later time point in individuals with
high gLFC-connectivity when compared to individuals with
low gLFC-connectivity, reﬂecting the signiﬁcant interaction
gLFC-connectivity  CSF-tau in the CSF-amyloid-b +
group.
Is global functional connectivity of the
left frontal cortex altered in
Alzheimer’s disease?
Next, we assessed whether gLFC-connectivity is reduced in
subjects with Alzheimer’s disease pathology. For DIAN, an
ANCOVA analysis showed that gLFC-connectivity was
reduced in mutation carriers compared to non-mutation
carriers (P = 0.0164), controlled for age, gender, education,
and site. However, markers of disease severity including
EYO, CSF-tau global PiB-PET uptake and hippocampal
volume were not associated with gLFC-connectivity in mu-
tation carriers, as tested by linear mixed effects analyses.
These results suggest that gLFC-connectivity is relatively
stable across the course of the disease. No associations be-
tween gLFC connectivity and any of the variables including
EYO, CSF-tau, global PiB-PET uptake, and hippocampal
volume were found in the non-mutation carriers. For
DELCODE, no differences in gLFC-connectivity were de-
tected between CSF-amyloid-b + and CSF-amyloid-b-
groups and no associations were found between gLFC-con-
nectivity and age or disease severity as assessed by CSF-tau,
CSF-amyloid-b42/40 ratio or hippocampal volume, neither
in the CSF-amyloid-b + nor CSF-amyloid-b– groups.
Associations between global
functional connectivity of the left
frontal cortex and education
We previously reported that education, a protective factor
in ageing and neurodegenerative diseases that is often used
Figure 3 Cognitive and biomarker changes. Cognitive and
biomarker changes as a function of Alzheimer’s disease severity.
MMSE is plotted separately for individuals with high versus low gLFC-
connectivity (as defined via median split). For the DIAN sample (A)
we plotted the standardized difference between mutation carriers
(MC) and non-mutation carriers (NC) against the EYO based on the
polynomial linear mixed models that best fit each marker. The plot
suggests that high gLFC-connectivity is associated with a delay of
cognitive decline towards a later timepoint with more progressed
levels of Alzheimer’s disease pathology. For the DELCODE sample
(B) we plotted the standardized difference between CSF-amyloid-b+
and CSF-amyloid-b subjects against CSF-tau levels. Congruent with
the DIAN sample, the plot suggests that cognitive decline is shifted to
a later time point in individuals with high levels of gLFC-connectivity.
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as a surrogate marker of reserve, is associated with higher
gLFC connectivity in prodromal Alzheimer’s disease
(Franzmeier et al., 2017b, c). In general agreement with
our previous ﬁndings, linear mixed models showed that
more years of education were associated with greater
gLFC-connectivity in ADAD mutation carriers at trend
level signiﬁcance (b/SE = 0.172/0.117, P = 0.072), and in
the CSF-amyloid-b + of the sporadic Alzheimer’s disease
sample (b/SE = 0.248/0.114, P = 0.033).
Discussion
The main ﬁnding of the current cross-sectional study is that
in participants with higher levels of gLFC-connectivity, the
effect of Alzheimer’s disease pathology on cognition was
attenuated compared to participants with lower levels of
gLFC-connectivity. These results were consistent in patients
with ADAD (DIAN) and sporadic Alzheimer’s disease
(DELCODE), suggesting that higher gLFC-connectivity
allows better maintenance of cognitive abilities during the
progression of Alzheimer’s disease.
From the perspective of dynamic biomarker development,
higher reserve should translate into a shift in the temporal
trajectory of cognitive decrease during the progression of
Alzheimer’s disease. Modelling the trajectory of cognitive
differences in MMSE and delayed recall against increases in
Alzheimer’s disease pathology (CSF-tau, EYO) showed for
participants with higher gLFC-connectivity a shift of the
cross-sectionally estimated trajectories of cognitive decline
to the right, i.e. to more progressed levels of Alzheimer’s
disease pathology. A strength of the DIAN study in ADAD
is the presence of relatively ‘pure’ Alzheimer’s disease path-
ology that can be tracked well ahead of dementia onset.
Still, the generalizability of ﬁndings to the more common
sporadic form of Alzheimer’s disease is important. Using
CSF-tau as a marker of disease severity that is closely
linked to cognitive symptoms in CSF-amyloid-b + subjects
of the DELCODE study, we replicated the ﬁndings of a
higher preservation of episodic memory and global cogni-
tion at more progressed levels of Alzheimer’s disease in
participants with higher levels of gLFC-connectivity. This
result is also consistent with our previous study in pro-
dromal Alzheimer’s disease, where higher gLFC-connectiv-
ity was associated with attenuated impact of Alzheimer’s
disease-related parietal glucose hypometabolism on
memory (Franzmeier et al., 2017b). Thus, the detection of
the association between gLFC-connectivity and reserve is
not speciﬁc to ADAD.
Since in ADAD the pathological development shows a
genetically-driven and stereotypical progression of
Alzheimer’s disease pathology, the question of why some
participants show higher or lower cognitive performance
than expected based on the pathological level is particularly
intriguing (Aguirre-Acevedo et al., 2016). In fact, the vari-
ability in cognitive decreases at any level of neurodegenera-
tion in ageing and Alzheimer’s disease is not a mere
random error of prediction based on pathology, but
shows a systematic bias (Reed et al., 2010; Zahodne
et al., 2013, 2015). Demographic factors such as education
or premorbid verbal cognitive abilities are associated with
higher than expected memory performance in ageing and
Alzheimer’s disease (Rentz et al., 2010; Ewers et al., 2013;
Soldan et al., 2013; Topiwala et al., 2015). However, such
protective factors are global in nature and difﬁcult to attri-
bute to structural or functional brain changes (Sole´-
Padulle´s et al., 2009; Arenaza-Urquijo et al., 2013;
Barulli and Stern, 2013). The current ﬁndings thus address
the need for an identiﬁcation of functional brain differences
that underlie reserve, i.e. the ability to maintain cognition
at a higher level in the presence of pathology.
Why is global connectivity of the LFC hub an important
characteristic of brain function and, in particular, reserve?
Global connectivity is a graph theoretical measure of the
class centrality that captures the connectivity of a node in
the whole connectome (Bullmore and Sporns, 2009). The
LFC is among the top 5% of globally connected brain re-
gions (Cole et al., 2010). Changes in hubs have particularly
strong global impact on the brain compared to connectivity
differences in other brain regions and are critical for the
resilience of brain networks to targeted attack (Achard
et al., 2006; Alstott et al., 2009; Santarnecchi et al.,
2015). Reduction of hub connectivity has been associated
with different neurodegenerative and psychiatric diseases
(Buckner et al., 2009; Crossley et al., 2014), while
increased hub connectivity is associated with better cogni-
tion (Cole et al., 2012; Liu et al., 2017). These results sup-
port the notion that connectivity of hubs is important for
sustaining cognition when developing Alzheimer’s disease.
The LFC is a hub closely linked to the fronto-parietal
control network. This functional network is particularly
important in ﬂexibly regulating the activity of different
functional networks (Chen et al., 2013). Such a network
regulation by the fronto-parietal control network is critical
for successful cognitive task performance (Kragel and
Polyn, 2015), particularly when other functional networks
become impaired (Cole et al., 2014). Thus, as a hub of the
fronto-parietal control network, the LFC may be of critical
importance for the regulation of other networks to support
successful cognition (Cole et al., 2015).
As shown by our control analyses, we could detect only
a single signiﬁcant interaction effect of RFC  EYO
on MMSE, which did not survive Bonferroni correction.
No effects for unimodal brain regions including M1 and
the visual cortex were observed. This result pattern suggests
that the ﬁndings are speciﬁc to the LFC, where predomin-
antly the LFC rather than the RFC supports reserve. Our
ﬁndings echo previous reports of resting state functional
MRI assessed connectivity in a similar LFC area to be crit-
ical for supporting functional network resilience during
simulated targeted attack of hub nodes (Santarnecchi
et al., 2015). Together, these ﬁndings suggest that gLFC-
connectivity is a feasible substrate of higher resilience of
cognition in the face of neuropathology.
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We found no decreases of gLFC-connectivity in sporadic
Alzheimer’s disease and only a mild reduction in ADAD,
suggesting the gLFC-connectivity is relatively stable in
Alzheimer’s disease. Previous studies reported that brain
hubs are in general implicated in neurodegenerative and
psychiatric diseases (Crossley et al., 2014); however, the
posterior and hippocampal hubs are selectivity impaired
in Alzheimer’s disease (Yu et al., 2017), potentially due
to their overlap with sites of early Alzheimer’s disease path-
ology (Buckner et al., 2009). This has been consistently
shown in sporadic and autosomal dominantly inherited
Alzheimer’s disease, where key hubs such as the posterior
cingulate, precuneus or hippocampus show disruptions
early in the disease course even prior to the onset of cog-
nitive symptoms (Sorg et al., 2007; Mevel et al., 2011;
Damoiseaux et al., 2012; Chhatwal et al., 2013). In con-
trast, we could show that connectivity of the LFC hub
region remains relatively unchanged across different
Alzheimer’s disease severity levels. Thus, the relatively
spared LFC hub may be well posed to subserve the main-
tenance of cognition during the course of Alzheimer’s dis-
ease. At the same time, gLFC-connectivity showed at no
stage of Alzheimer’s disease an increase, thus we found
no indication of a temporary compensatory increase in re-
sponse to pathology. Rather, differences in gLFC-connect-
ivity may have existed before disease onset. In line with our
previous study (Franzmeier et al., 2017c), we observed in
the current study an association between more years of
education and higher gLFC-connectivity, suggesting that
gLFC-connectivity is possibly shaped by early life experi-
ences, consistent with view of cognitive reserve (Stern,
2012). Thus, higher gLFC-connectivity is most likely a
pre-morbid existing trait that enables to better cope with
pathological changes during diseases such as Alzheimer’s
disease.
For the interpretation of the current results, potential
caveats should be taken into consideration. First, as a
measure of hubness, we used global connectivity, which
in graph theoretical terms is also called weighted degree
centrality. It should be noted that alternative measures of
centrality have been proposed such as the page-rank cen-
trality and eigenvector centrality (Zuo et al., 2012).
However, we chose the current global connectivity measure
as it is the most widely used index of centrality applied in
human brain connectomics (Buckner et al., 2009; Wang
et al., 2010; Cole et al., 2012, 2015; Zuo et al., 2012;
Santarnecchi et al., 2015; Franzmeier et al., 2017a, b).
Thus, in order to facilitate comparability with previous
ﬁndings, we focused on the current measure of global
connectivity.
Second, the current study included mostly subjects within
the range of asymptomatic or mild cognitive impairment of
Alzheimer’s disease. Thus, a generalization to more severe
dementia stages needs to be tested in future studies. It is
conceivable that the inﬂuence of the LFC or any substrate
of reserve wanes as the disease becomes more severe and
network failure becomes more profound (Jones et al.,
2016).
Third, in order to facilitate comparability across samples
we focused our analyses on the MMSE and logical memory
delayed free recall scores. A more comprehensive testing of
episodic memory is desirable, but was not possible since the
overlap of memory tests between the studies was limited. In
DELCODE, the widely used verbal word list learning test
as included in the ADAS-Cog battery was also available,
for which we found the same result pattern as for the lo-
gical memory delayed free recall and MMSE. The current
results are also consistent with our previous results on
gLFC-connectivity on memory, where more comprehensive
memory tests were used (Franzmeier et al., 2017b). Still,
future studies may utilize a wider breadth of neuropsycho-
logical tests to capture global cognitive and memory abil-
ities in a more comprehensive manner.
Fourth, we included only cross-sectional data rather than
longitudinal assessment, thus, individual trajectories of cog-
nitive changes could not be assessed. However, the trajec-
tories assessed across the spectrum of Alzheimer’s disease
severity at the cross-sectional level are highly consistent
with the longitudinal trajectories of biomarker changes.
Thus, especially in ADAD, the cross-sectionally estimated
trajectories may be a proxy of the expected trajectories
when assessed longitudinally, which awaits further valid-
ation once sufﬁcient longitudinal data become available in
studies such as DIAN or DELCODE.
Lastly, we assessed only Alzheimer’s disease among other
neurodegenerative diseases. Resilience of cognition to
pathologies has also been reported in fronto-temporal de-
mentia, vascular dementia or multiple sclerosis (Zieren
et al., 2013; Martins Da Silva et al., 2015; Premi et al.,
2017). It is an open question whether gLFC-connectivity
subserves reserve also in those disorders.
As an outlook, the current identiﬁcation of the LFC hub
may provide a suitable target for therapeutic intervention.
Previous studies have shown that connectivity of frontal
hubs can be enhanced by cognitive training (Takeuchi
et al., 2017) and higher frontal connectivity can be induced
by transcranial magnetic stimulation or transcranial direct-
current stimulation (Chen et al., 2013; Kim et al., 2016).
Enhancement of gLFC-connectivity by stimulation tech-
niques, cognitive training, or physical exercise (Duzel
et al., 2016) may provide an attractive non-invasive second-
ary prevention approach to sustain cognitive resilience in
Alzheimer’s disease (Clark and Parasuraman, 2014).
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